In the battle against type 1 diabetes (T1D), one researcher at the Medical University of South Carolina (MUSC) is leading a ...

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...

A new study shows human immune systems differ across populations, raising new questions for medicine and global drug research ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in ...

ImmunityBio recently reported positive clinical data from its ANKTIVA (nogapendekin alfa inbakicept) program in non-small ...

Adenosine deaminase acting on RNA (ADAR) is the enzyme responsible for adenosine-to-inosine (A-to-I) RNA editing, a process ...

Scientists have made a discovery that helps explain why humans and animals are so susceptible to contracting tuberculosis (TB ...

Neurodegenerative diseases, traditionally viewed as driven by neuronal decline, are increasingly recognized to involve ...

Scientists have uncovered how a vitamin A metabolite can suppress anti-cancer immunity. Scientists at the Princeton University Branch of the Ludwig Institute for Cancer Research have uncovered new ...

IV therapy is redefining modern self-care in 2026. Experts explain how customised IV drips for glow, immunity, and energy are ...

Shares of ImmunityBio rose to a three-month high after the company reported positive results from clinical trials of its Anktiva immunotherapy to treat lung cancer patients. The stock closed the ...

Cell cycle checkpoint-related genes (CCCRGs) are implicated in the development and progression of hepatocellular carcinoma ...